Tecfidera (Delayed-release Dimethyl Fumarate) Benefits Newly Diagnosed MS Patients, According to Study

Dimethyl Fumarate Allergen Molecule
Image Source: ALLPOSTERS

Newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) show significant improvements when treated with delayed-release dimethyl fumarate (DMF), especially in terms of reduction in confirmed disability progression. The study, “Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Multiple Sclerosis Using a Composite Measure of Disability,” was recently presented at the June 1-4 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Transient hair loss during treatment with Tecfidera (dimethyl-fumarate) for MS: STUDY

Image Source: GUANGSHUCHEMICALFACTORYC.LTD

Tecfidera (Dimethyl Fumarate), a Common MS Drug, Found to Work Independently of Nrf2 Pathway

A commonly prescribed MS medication may act to modulate the immune system. The finding is described in the article “Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2,“ published in  the journal Proceedings of the National Academy of Sciences.

Promising New Treatments for MS: VIDEO

MS is a chronic disease that affects the nervous system. Nerves are coated in a protective covering called myelin, which also speeds up the transmission of nerve signals. People with MS experience progressive deterioration of myelin.